Bortezomib in Treating Patients With Recurrent Glioma
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Phase I trial to study the effectiveness of bortezomib in treating patients who have
recurrent glioma. Bortezomib may stop the growth of tumor cells by blocking the enzymes
necessary for tumor cell growth